BNP/CALL/ABBVIE/200/0.1/19.12.25 Stock

DE000PC4AE74

Real-time Boerse Frankfurt Warrants 09:20:14 2024-06-20 EDT
0.97 ^EUR	0.00%

Current month	+64.41%
1 month	+25.97%

Comparison chart between the derivative product and it's underlying value

End-of-day quotes

Chart ABBVIE INC.

Latest news about ABBVIE INC.

AbbVie Appoints Roxanne S. Austin as Lead Independent Director of the Board of Directors	08:01am	PR
AbbVie: FDA approval in ulcerative colitis	06-19	CF
U.S. FDA Approves SKYRIZI® (risankizumab-rzaa) for Ulcerative Colitis, Expanding AbbVie's Portfolio Across Inflammatory Bowel Disease	06-18	PR
AbbVie's Skyrizi Gets FDA Approval to Treat Certain Instances of Ulcerative Colitis	06-18	DJ

More news

Quotes 5-day view

Date	Price	Change
24-06-20	0.97	0.00%
24-06-19	0.97	-1.02%
24-06-18	0.98	+10.11%
24-06-17	0.89	+1.14%
24-06-14	0.88	+11.39%

Real-time Boerse Frankfurt Warrants

Last update June 20, 2024 at 09:20 am

More quotes

Static data

Product type	Plain-Vanilla-Warrants
Buy / Sell	CALL
Underlying	ABBVIE INC.
Issuer	BNP Paribas
WKN	PC4AE7
ISIN	DE000PC4AE74
Date issued	2024-01-31
Strike	200 $
Maturity	2025-12-19 (547 Days)
Parity	10 : 1
Emission price	0.66 €
Emission volume	N/A
Settlement	cash
Currency	EUR

Technical Indicators

Highest since issue	1.56 €
Lowest since issue	0.45 €
Spread	0.06 €
Spread %	5.77%

Company Profile

AbbVie Inc. specializes in therapeutic drug research and development. Its products are intended for treating rheumatoid arthritis, psoriasis, Crohn's disease, thyroid disease, Parkinson's disease, HIV, complications of mucoviscidosis, low testosterone levels, and complications associated with chronic renal disease. Net sales are distributed geographically as follows: the United States (77.1%), Germany (2.3%), Canada (2%), Japan (1.9%), China (1.7%), France (1.4%), Spain ( 0.9%), Italy (0.9%), Australia (0.9%), Brazil (0.8%), United Kingdom (0.8%) and others (9.3%).

Sector

More about the company